Combination therapy for the treatment of cancer

Abstract

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

1 - 42 . (canceled) 
     
     
         43 . A pharmaceutical combination consisting essentially of
 (1) a first agent which is Compound A1 described by Formula A1 below or a pharmaceutically acceptable salt thereof:   
       
         
           
           
               
               
           
         
         and 
         (2) a second agent which is letrozole. 
       
     
     
         44 . The combination of claim  42 , wherein the agents are administered simultaneously, separately or sequentially. 
     
     
         45 . The combination of claim  42 , wherein the agents are administered simultaneously. 
     
     
         46 . The combination of claim  42 , wherein the agents are administered separately. 
     
     
         47 . The combination of claim  42 , wherein the agents are sequentially. 
     
     
         48 . A method of palliative treating breast cancer consisting essentially of administering to a subject
 (1) a first agent which is Compound A1 described by Formula A1 below or a pharmaceutically acceptable salt thereof:   
       
         
           
           
               
               
           
         
         and 
         (2) a second agent which is letrozole. 
       
     
     
         49 . The method of  claim 48  where in the breast cancer is an estrogen receptor positive breast cancer. 
     
     
         50 . The method of  claim 48  wherein the breast cancer is a HER2− breast cancer. 
     
     
         51 . The method of  claim 48  where in the breast cancer is an estrogen receptor positive, HER2− breast cancer. 
     
     
         52 . The method of  claim 48 , wherein the agents are administered simultaneously, separately or sequentially. 
     
     
         53 . The method of  claim 48 , wherein the agents are administered simultaneously. 
     
     
         54 . The method of  claim 48 , wherein the agents are administered separately. 
     
     
         55 . The method of  claim 48 , wherein the agents are sequentially.